Combined chemotherapy with gemcitabine and cisplatin for metastatic urothelial carcinomas in patients 80 years of age and over.

Abstract

BACKGROUND This retrospective study aimed to determine the efficacy and toxicity of a combined chemotherapeutic regimen of gemcitabine and cisplatin (GC) for the treatment of metastatic urothelial carcinomas (UCs) in patients 80 years of age and over. PATIENTS AND METHODS Twelve patients who were at least 80 years old and had been diagnosed with metastatic UC were treated with GC. The patient cohort consisted of 9 men and 3 women, with a median age of 83 (range 80-84) years. The median follow-up was 54 (range 14-80) months. RESULTS Five out of the 12 patients (42%) showed an objective response, with two achieving a clinically complete response and three a partial response with GC. The median time to progression was 6 months, and the median overall survival was 14 months. The grade 3 and 4 toxicities of the regimen were primarily hematological, including anemia (33%), neutropenia (58%), and thrombocytopenia (50%). No grade 3 or 4 non-hematological toxicities were found. CONCLUSION GC appears to be an effective and well-tolerated regimen for the treatment of metastatic UCs in very old patients.

5 Figures and Tables

Cite this paper

@article{Tanji2010CombinedCW, title={Combined chemotherapy with gemcitabine and cisplatin for metastatic urothelial carcinomas in patients 80 years of age and over.}, author={Nozomu Tanji and Tetsuya Fukumoto and Noriyoshi Miura and Yutaka Yanagihara and Kouji Azuma and Toyokazu Sasaki and Takayasu Nishida and Tadahiko Kikugawa and Kenji Shimamoto and Katsunori Aoki and Masayoshi Yokoyama}, journal={Anticancer research}, year={2010}, volume={30 9}, pages={3839-43} }